Strategic partnership between Mission Bio and Fulgent
Genetics will enable drug developers to leverage single-cell
multi-omics for biomarker discovery, clinical research, and
single-cell MRD development at scale
SOUTH
SAN FRANCISCO, Calif., April 11,
2023 /PRNewswire/ -- Mission Bio, Inc., the
pioneer in high-throughput single-cell DNA and multi-omics
analysis, today announced that it has entered into an agreement
with Fulgent Genetics (NASDAQ: FLGT), a technology-based company
with well-established clinical diagnostic and therapeutic
development businesses. Fulgent Genetics is now able to offer
single-cell multi-omics on the Tapestri Platform on its fully
customizable menu of services, including whole genome, whole exome,
RNA sequencing, tumor profiling, methylation sequencing, liquid
biopsy, single-cell sequencing, spatial biology, and pathology
services to support its growing pharma client demands.
Additionally, Fulgent Genetics will evaluate the Tapestri Platform
for applications in clinical development to streamline the drug
development and approval process.
Over the last ten to fifteen years, there has been a paradigm
shift in clinical trials towards precision oncology by using
biomarkers to select or enrich trial cohorts. The Tapestri
Platform's ability to do single-cell analysis of genotype and
phenotype from the same cell can provide the sensitivity and
resolution for biomarker discovery unattainable by current bulk
methods. Single-cell resolution can reveal treatment resistance
mechanisms that may help to better stratify patients in clinical
trials. While on treatment, residual levels of disease can be
detected with the high sensitivity of single-cell analysis.
Characterizing clonal heterogeneity and tracking clonal evolution
during treatment can potentially guide adaptive and rational
combination therapies for better patient stratification and better
clinical trial outcomes.
"The increasing adoption of the Tapestri Platform for
translational research and clinical development by many cancer
centers and global pharma companies demonstrates the necessity of
single-cell multi-omics," said Dr. Hanlin
(Harry) Gao M.D., Ph.D., D.A.B.M.G., F.A.C.M.G., Chief
Scientific Officer of Fulgent Genetics. "The relationship between
Fulgent Genetics and Mission Bio will make it easier and faster for
biopharmaceutical customers to generate data for more precise
clinical trials."
"Fulgent Genetics' full scope, end-to-end service and
comprehensive genomic portfolio is the perfect one-stop shop for
pharma customers," said Todd Druley,
M.D., Ph.D., Chief Medical Officer of Mission Bio. "While some
pharma customers can and still do partner with us through our
internal Pharma Assay Development (PAD) services, this
collaboration provides another option for them to leverage the
single-cell multi-omics expertise and full suite of solutions
offered by Fulgent Genetics, particularly as they complete the
validation of the Tapestri Platform in their CAP CLIA lab in the
near future."
Customers today have access to the Tapestri Platform and its
full breadth of single-cell multi-omics and scMRD assays through
Fulgent Genetics' labs.
To learn more about Mission Bio and the Tapestri® Platform,
please visit www.missionbio.com.
About Mission Bio
Mission Bio is a life sciences
company that accelerates discoveries and cures for a wide range of
diseases by equipping researchers with the tools they need to
better measure and predict our resistance and response to new
therapies. Mission Bio's multi-omics approach improves
time-to-market for new therapeutics, including innovative cell and
gene therapies that provide new pathways to health. Founded in
2014, Mission Bio has secured investment from Novo Growth, Cota
Capital, Agilent Technologies, Mayfield Fund, and others.
The company's Tapestri Platform gives researchers around the
globe the power to interrogate every molecule in a cell together,
providing a comprehensive understanding of activity from a single
sample. Tapestri is the only commercialized multi-omics platform
capable of analyzing DNA and protein simultaneously from the same
sample at single-cell resolution. The Tapestri Platform is being
utilized by customers at leading research centers, pharmaceutical,
and diagnostics companies worldwide to develop treatments and
eventually cures for cancer.
About Fulgent
Fulgent is a technology-based company
with a well-established clinical diagnostic business and a
therapeutic development business. Fulgent's clinical diagnostic
business offers molecular diagnostic testing services,
comprehensive genetic testing, and high-quality anatomic pathology
laboratory services designed to provide physicians and patients
with clinically actionable diagnostic information to improve the
quality of patient care. Fulgent's therapeutic development business
is focused on developing drug candidates for treating a broad range
of cancers using a novel nanoencapsulation and targeted therapy
platform designed to improve the therapeutic window and
pharmacokinetic profile of new and existing cancer drugs. The
company aims to transform from a genomic diagnostic business into a
fully integrated precision medicine company.
Media Contact
Consort Partners for Mission
Bio
missionbio@consortpartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/mission-bio-partners-with-fulgent-genetics-to-broaden-accessibility-of-single-cell-multi-omics-for-drug-development-and-clinical-research-301793829.html
SOURCE Mission Bio